AbbVie settles Rinvoq patent disputes, pushing back generics to 2037
AbbVie (NYSE: ABBV) said in a regulatory filing that it has resolved all litigation with manufacturers seeking to market generic versions of its immunosuppressant Rinvoq (upadacitinib). The settlement means that no copycat versions are expected in the US before April 2037, assuming pediatric exclusivity is granted.
The move is a win for the drugmaker as it works to extend the lifespan of one of its key growth drivers. Shares in AbbVie rose more than 5% on the news, reflecting investor confidence that Rinvoq can continue to offset erosion from the loss of exclusivity for Humira (adalimumab), once the world’s top-selling drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze